U.K. cost watchdog nixes pricey biologics for moderate rheumatoid arthritis

Carly Helfand

The 's effectiveness gatekeepers are giving their final blessing to a slew of –but only for patients with advanced forms of the disease. And drugmakers aren't exactly happy about it.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS